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Prothrombin is activated to thrombin by two sequential factor Xa-catalyzed cleavages, at Arg271 followed by
cleavage at Arg320. Factor Va, along with phospholipid
and Ca2ⴙ, enhances the rate of the process by 300,000fold, reverses the order of cleavages, and directs the
process through the meizothrombin pathway, characterized by initial cleavage at Arg320. Previous work indicated reduced rates of prothrombin activation with
recombinant mutant factor Va defective in factor Xa
binding (E323F/Y324F and E330M/V331I, designated factor VaFF/MI). The present studies were undertaken to
determine whether loss of activity can be attributed to
selective loss of efficiency at one or both of the two
prothrombin-activating cleavage sites. Kinetic constants for the overall activation of prothrombin by prothrombinase assembled with saturating concentrations
of recombinant mutant factor Va were calculated, prothrombin activation was assessed by SDS-PAGE, and
rate constants for both cleavages were analyzed from
the time course of the concentration of meizothrombin.
Prothrombinase assembled with factor VaFF/MI had decreased kcat for prothrombin activation with Km remaining unaffected. Prothrombinase assembled with saturating concentrations of factor VaFF/MI showed significantly
lower rate for cleavage of plasma-derived prothrombin at
Arg320 than prothrombinase assembled with saturating
concentrations of wild type factor Va. These results were
corroborated by analysis of cleavage of recombinant prothrombin mutants rMz-II (R155A/R284A/R271A) and
rP2-II (R155A/R284A/R320A), which can be cleaved only
at Arg320 or Arg271, respectively. Time courses of these
mutants indicated that mutations in the factor Xa binding site of factor Va reduce rates for both bonds. These
data indicate that the interaction of factor Xa with the
heavy chain of factor Va strongly influences the catalytic activity of the enzyme resulting in increased rates
for both prothrombin-activating cleavages.
Blood coagulation is necessary to stop blood from leaking out
of the vasculature and involves a number of specific serine
proteases that are activated by limited proteolysis. The end
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result of this process is the conversion of prothrombin to thrombin, which in turn cleaves fibrinogen to produce the insoluble
fibrin mesh (1). Prothrombin is activated physiologically by the
prothrombinase complex, which is composed of the non-enzymatic cofactor, factor Va, the enzyme, factor Xa, and the substrate, prothrombin, associated on a cell membrane surface in
the presence of Ca2⫹ (2, 3). Activation of prothrombin to thrombin is a consequence of two cleavages at Arg271 and Arg320 by
factor Xa. Depending on the order of peptide bond cleavage,
different intermediates are formed (Fig. 1). Initial cleavage at
Arg271 will produce fragment 1䡠2 and prethrombin-2, whereas
initial cleavage at Arg320 results in the formation of meizothrombin, which has optimal amidolytic activity but diminished clotting activity (4 –13). The existence of these two pathways has long been established (4 –9), and the kinetics of the
rate of cleavage determined (10 –13). Although factor Xa alone
cleaves prothrombin sequentially at Arg271 followed by Arg320
to produce thrombin (Fig. 1, pathway I), the rate of the overall
reaction for thrombin formation is slow and incompatible with
survival. The prothrombinase complex catalyzes the activation
of prothrombin following the second pathway (Arg320 followed
by Arg271, Fig. 1, pathway II), resulting in a 300,000-fold increase in the rate of the overall reaction compared with the rate
of prothrombin activation observed with factor Xa alone and
represents the physiological relevant pathway for prothrombin
activation (3, 12, 13). Although both cleavages are phospholipiddependent, only initial cleavage of prothrombin at Arg320 is
strictly dependent on factor Va. The overall increase in the
catalytic efficiency of prothrombinase when compared with the
activation of prothrombin by factor Xa alone appears to arise
from a 100-fold decrease in the Km and a 3,000-fold increase in
the kcat of the enzyme (10, 14 –16).
Human prothrombin is composed of 579 amino acids and
circulates in blood at a concentration of 1.4 M (17). Although
the importance of the contribution of factor Va to the activity of
factor Xa for rapid thrombin generation by prothrombinase at
the place of vascular injury has been long established, the
consequence of the interaction of the cofactor with the components of prothrombinase and the molecular mechanism by
which factor Va reverses the order of cleavages and increases
the rate of the overall catalysis remain enigmatic and are the
subjects of intense investigation. Proteolytic processing of factor V by thrombin at Arg709, Arg1018, and Arg1545 is required for
the interaction of the cofactor with the members of prothrombinase and produces a factor Va molecule that consists of a
heavy chain (Mr 105,000) and a light chain (Mr 74,000) (18, 19).
Although both chains of factor Va and Ca2⫹ are required for the
interaction with factor Xa, only the heavy chain of the cofactor
binds prothrombin in a Ca2⫹-independent manner (20 –22).
Cleavage of factor Va by APC at Arg506/Arg679 results in de-
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creased affinity of the molecule for factor Xa and eliminates its
interaction with prothrombin (21, 23, 24). Subsequent cleavage
of the membrane-bound cofactor at Arg306, completely abolishes the ability of factor Va to interact with factor Xa (23, 24).
The interaction of factor Va with factor Xa and prothrombin
has been long established as a requirement for optimum rates
of prothrombin activation (3, 4, 6, 10, 11, 14, 25, 26). However,
the consequences of these associations on the mechanism of
catalysis and the discrete amino acid regions from the molecules that are involved in protein-protein interaction have remained puzzling. Furthermore, earlier findings as well as data
using mutant prothrombin molecules have suggested that the
rate of cleavage at Arg320 largely benefits from incorporation of
factor Va into prothrombinase while the rate of cleavage at
Arg271 appears to be less affected (12, 13). We have recently
identified binding sites for factor Xa and prothrombin in the
middle portion and the COOH terminus of the heavy chain of
factor Va, respectively (27–31). Our findings suggested that
factor Va has a crucial effect on prothrombinase activity, orchestrating the spatial arrangement of enzyme and substrate,
ultimately directing cleavage and activation of prothrombin by
factor Xa at two spatially distinct proteolytic sites (28). The
present study was undertaken to identify and understand the
molecular mechanisms underlying the contribution factor Va to
the two factor Xa-mediated prothrombin-activating cleavages
following its incorporation into prothrombinase.
EXPERIMENTAL PROCEDURES

Materials, Reagents, and Proteins—L-␣-Phosphatidylserine (PS)1
and L-␣-phosphatidylcholine (PC) were from Avanti Polar Lipids
(Alabaster, AL). Normal reference plasma and the chromogenic substrate
Spectrozyme-TH were from American Diagnostica, Inc. (Greenwich, CT).
The thromboplastin reagent for the clotting assays was purchased from
Organon Teknika Corp. (Durham, NC). The fluorescent thrombin
inhibitor dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide (DAPA),
RVV-factor V activator, human factor Xa, human thrombin, a sheep
anti-human factor V polyclonal antibody, and the monoclonal antibody
␣hFV#1 coupled to Sepharose were from Hematologic Technologies Inc.
(Essex Junction, VT). Human prothrombin was purified according to
the procedure detailed by Bajaj and Mann (32). A final step was included in the purification procedure that included the use of hydroxyapatite column chromatography (Bio-Rad) to eliminate a proteolytic
product from prothrombin that was consistently present in all final
prothrombin preparations. Recombinant prothrombin molecules rMZ-II
(prothrombin with the substitutions Arg155 3 Ala, Arg284 3 Ala, and
Arg271 3 Ala) and rP2-II (prothrombin with the substitutions Arg155 3
Ala, R284 3 Ala, and R320 3 Ala) were prepared and purified as
described previously (13, 33). The cDNA for factor V was purchased
from American Type Tissue Collection (ATCC number 40515 pMT2-V,
Manassas, VA). The sequence of this cDNA molecule is identical to the
cDNA published by Jenny et al. (34). All restriction enzymes were from
New England Biolabs (Beverly, MA), and all other molecular biology
and tissue culture reagents and media were from Invitrogen or as
indicated. Human plasma factor V and factor Va were purified and
concentrated using methodologies previously described employing the
monoclonal antibody ␣hFV#1 coupled to Sepharose and heparin-Sepharose (30, 35). The cofactor activity of the plasma-derived and recombinant factor Va preparations was measured by a clotting assay using
factor V-deficient plasma using an automated coagulation analyzer
(START-4, Diagnostica Stago, Parsippany, NJ). Phospholipids vesicles

1
The abbreviations used are: PS, L-␣-phosphatidylserine; APC, activated-protein C; PC, L-␣-phosphatidylcholine; PCPS, small unilamellar
phospholipids vesicles composed of 75% PC and 25% PS (w/w); DAPA,
dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide; rMZ-II, prothrombin
with the substitutions Arg155 3 Ala, Arg284 3 Ala, and Arg271 3 Ala;
rP2-II, prothrombin with the substitutions Arg155 3 Ala, Arg284 3 Ala,
and Arg320 3 Ala; factor VaFF, recombinant human factor Va with the
mutations Glu323 3 Phe and Val324 3 Phe; factor VaMI, recombinant
human factor Va with the mutations Glu330 3 Met and Val331 3 Ile;
factor VaFF/MI, quadruple mutant, recombinant human factor Va with
the mutations Glu323 3 Phe and Val324 3 Phe and Glu330 3 Met and
Val331 3 Ile; TAP, tick anticoagulant protein.

FIG. 1. Schematic of the pathways for the activation of human
prothrombin. Prothrombin contains ten ␥-carboxyglutamic acid residues (hatched region), two kringle domains (checkered region), and a
serine protease domain (black region) (17). Initial cleavage at Arg271 by
membrane-bound factor Xa in the absence of factor Va, results in the
generation of fragment 1䡠2 and prethrombin-2 followed by subsequent
cleavage at Arg320 resulting in thrombin formation (pathway I). Initial
cleavage at Arg320 by prothrombinase (factor Va bound to factor Xa on
a membrane surface in the presence of Ca2⫹) results in the production
of a catalytically active intermediate (meizothrombin), which has the
same molecular weight as prothrombin under non-reducing conditions.
Following reduction, the intermediate gives rise to fragment 1䡠2-A and
the B chain of thrombin. Subsequent cleavage of this intermediate at
Arg271 produces thrombin and fragment 1䡠2 (pathway II). Once formed
thrombin also cleaves prothrombin at Arg155 to form prethrombin-1,
and at Arg284 to form the A chain of thrombin minus thirteen amino
acids (dashed arrows).
composed of 75% PC and 25% PS (referred to as PCPS vesicles throughout the manuscript) were prepared as previously described (36). The
concentration of phospholipid vesicles was determined by phosphorous
assay as described earlier and is given as the concentration of inorganic
phosphate (37).
Mutagenesis and Transient Expression of Recombinant Factor V Molecules—All mutant factor V molecules described herein were synthesized by PCR-based methods as described (28, 31). The activity and the
integrity of the molecules were verified before and after activation by
thrombin by clotting assays using factor V-deficient plasma and by
SDS-PAGE followed by Western blotting using well characterized
monoclonal antibodies (provided by Dr. Ken Mann, Department of
Biochemistry, University of Vermont).
Measurement of Rates of Thrombin Formation in a Prothrombinase
Assay—All factor V species (plasma and recombinant) were activated
with thrombin for 15 min at 37 °C followed by the addition of diisopropylfluorophosphate (2 mM, Sigma). The assay verifying the activity of
the recombinant molecules was conducted as described by measuring
thrombin formation by the change in the absorbance of a chromogenic
substrate at 405 nm (Spectrozyme-TH) monitored with a Thermomax
microplate reader (Molecular Devices, Sunnyvale, CA) (31). Absorbance
at 405 nm was compared with a standard curve prepared daily using
purified thrombin (0 –50 nM).
For the functional calculation of the apparent dissociation constants
(Kapp
D ) between the recombinant factor Va molecules and factor Xa,
experiments were performed in the presence of a limited concentration
of factor Xa (between 15 and 30 pM) and varying concentrations of factor
Va (up to 20 nM). The initial rates of thrombin generation in the various
assay mixtures under the conditions employed were linear, and in all
experiments no more than 10% of prothrombin was consumed during
the initial course of the assay. The initial rate of the formation of
thrombin (initial velocity in nM䡠IIa䡠min⫺1) was calculated, and the data
were analyzed and plotted assuming a 1:1 stoichiometry between factor
Va and factor Xa (one binding site) using the software Prizm (GraphPad, San Diego, CA) as described (27, 38). Once the value of the Kapp
for
D
the bimolecular interaction of each species of factor Va with factor Xa
was determined, the amount of recombinant factor Va required to
completely saturate factor Xa and provide similar amount of enzyme
(prothrombinase) when using various mutant recombinant factor Va
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TABLE I
Rate of activation of native plasma-derived prothrombin in the presence of prothrombinase assembled with
various recombinant factor Va species
Enzyme

Factor Xa alone
Prothrombinase
Prothrombinase
Prothrombinase
Prothrombinase

with
with
with
with

wild type factor Va
factor VaFF
factor VaMI
factor VaFF/MI

Prothrombin consumptiona

Decrease

moles consumed䡠s⫺1䡠mole factor Xa⫺1

-fold

0.0 ⫾ 0.09
15.4 ⫾ 0.9
4.9 ⫾ 0.4
6.7 ⫾ 0.3
0.92 ⫾ 0.08

3.14
2.3
16.7

a
The rates of prothrombin consumption were obtained following scanning densitometry of the gels shown in Fig. 2. The final rate of prothrombin
consumption in the presence of prothrombinase assembled with the various factor Va species, was extracted following plotting of the data according
to the method described under “Experimental Procedures.”

FIG. 2. Analysis of the activation of plasma-derived prothrombin by prothrombinase assembled with mutant factor Va molecules.
Plasma-derived prothrombin was incubated with PCPS vesicles, DAPA, and various factor Va molecules (10 nM). The reaction was started by the
addition of factor Xa. At selected time intervals aliquots of the reactions were withdrawn and treated as described under “Experimental
Procedures.” M represents the lane with the molecular weight markers (from top to bottom): Mr 98,000, Mr 64,000, Mr 50,000, and Mr 36,000. Lanes
1–19 represent samples from the reaction mixture before (0 min) the addition of factor Xa and 20 s, 40 s, 60 s, 80 s, 100 s, 120 s, 140 s, 160 s, 180 s,
200 s, 220 s, 240 s, 5 min, 6 min, 10 min, 20 min, 30 min, and 60 min, respectively, following the addition of factor Xa. A, factor Xa alone and no
factor Va; B, prothrombinase assembled with plasma-derived factor Va; C, prothrombinase assembled with wild type factor Va; D, prothrombinase
assembled with factor VaFF; E, prothrombinase assembled with factor VaMI; F, prothrombinase assembled with factor VaFF/MI. For the easy reading
of the manuscript the factor Va species used for the reconstitution of prothrombinase are also shown under each panel. The identity of each
fragment generated following cleavage of prothrombin by prothrombinase was verified in separate experiments by NH2-terminal sequencing and
comparison of the data with the primary structure of prothrombin (17). The prothrombin-derived fragments are numbered consecutively from the
NH2 terminus of prothrombin and are shown as follows: II, prothrombin (amino acid residues 1–579); F1䡠2-A, fragment 1䡠2-A chain (amino acid
residues 1–320); F1䡠2, fragment 1䡠2 (amino acid residues 1–271); B, B chain of thrombin (amino acid residues 321–579); F1, fragment 1 (amino acid
residues 1–155); P1, prethrombin-1 (amino acid residues 156 –579); P2, prethrombin-2 (amino acid residues 272–579) (17). Gels were submitted to
scanning densitometry as described under “Experimental Procedures,” and the rates of prothrombin consumption are reported in Table I.
molecules (between 90% and ⬎99% saturation) can be calculate as
abundantly described in the literature (39, 40).
For the calculation of the kinetic constants of prothrombinase assembled with the various recombinant mutant factor Va molecules as well
as with plasma factor Va (Km and Vmax), experiments were conducted in
the presence of a limited amount of factor Xa (5 pM) in the presence of
a fixed and saturating concentration of factor Va (5–30 nM) while

varying the amount of the substrate (plasma-derived prothrombin)
from 25 nM to 6 M. Kinetic constants (Km and kcat) were extracted
directly from the plotted data.
Additivity of the Mutational Effects of Substitutions 323EY324 3 FF
and 330EV331 3 MI on Prothrombinase Function—Prothrombinase is
composed of factor Va and factor Xa assembled on a membrane surface
in the presence of divalent metal ions. Any perturbation in the inter-
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action between the two molecules caused by a mutation may influence
or modify the stability of the catalytic site of the enzyme and can be
measured by the change in the transition-state stabilization of free
energy for prothrombin activation as extensively described (41– 45).
Thus, the consequence of the mutations in factor Va affecting factor Xa
catalytic efficiency and their additivity can be measured relative to the
change in transition-state stabilization free energy (⌬⌬G‡) of the enzyme as previously established (41– 45).
To assess whether the two sets of mutations affecting the interaction
of factor Va with factor Xa (E323F/Y324F; E330M/V331I) energetically
interact, four separate free energies associated with the catalytic efficiency of prothrombinase must be measured: ⌬Gwt, the functional free
energy in prothrombinase assembled with wild-type factor Va; ⌬GFF,
the functional free energy in prothrombinase assembled with factor
VaFF; ⌬GMI, the functional free energy in prothrombinase assembled
with factor VaMI; and ⌬GFF/MI, the functional free energy in prothrombinase assembled with factor VaFF/MI. In general, the perturbation to
the function of prothrombinase assembled with wild type factor Va
(state A), caused by a mutation in factor Va (state B) affecting the
transition state, can be defined in general as follows,
⌬⌬G B⫽⌬GB⫺⌬GA

(Eq. 1)

and because we are measuring prothrombinase activity assembled in
the presence of various factor Va molecules against the same substrate
(prothrombin), the changes in transition-state stabilization free energy
(⌬⌬G‡) during catalysis caused by a mutation in factor Va (state B) can
be calculated from the following general equation,
⌬⌬G ‡A3 B ⫽ ⫺ RT ln[(kcat/Km)B/(kcat/Km)A]
⫺1

(Eq. 2)
⫺1

with R being the universal gas constant (2 cal䡠K 䡠mol ), T the
absolute temperature in Kelvin (298 K in all our experiments), kcat is
the turnover number, and Km is the Michaelis-Menten constant for
prothrombinase assembled with either wild-type or mutant factor Va
molecules. In addition, the free energy of the interaction between two
mutations in factor Va (A 3 B and A 3 C; where A represents the
wild type factor Va, B and C represent cofactor molecules with two
different mutations, and B/C represent a double mutant factor Va
molecule) can be calculated with the following general equation
(42– 45).
⌬⌬G int ⫽ ⌬⌬GA3 B/C ⫺ (⌬⌬GA3 B ⫹ ⌬⌬GA3 C)

(Eq. 3)

The term ⌬⌬Gint reflects an exchange in free energy between the side
chains of the amino acids studied (i.e. 323EY324 and 330EV331). A value of
⌬⌬Gint ⬎0 or ⬍0 implies that the side chains of the mutated amino acids
interact with each other, reducing or enhancing, respectively, the catalytic efficiency of prothrombinase.
Analysis of Prothrombin Activation by Gel Electrophoresis—Plasmaderived prothrombin or recombinant mutant prothrombin molecules
(1.4 M) were incubated with PCPS vesicles (20 M), DAPA (50 M), and
factor Va (10 nM or as indicated in the figure legends) in the presence of
5 mM Ca2⫹ in 20 mM Tris, 0.15 M NaCl, pH 7.4. The reaction was started
by the addition of factor Xa (0.5 nM or as indicated in the figure legends)
at room temperature. At selected time intervals (also indicated in the
figure legends) aliquots from the reaction were removed and immediately diluted into 2 volumes of 0.2 M glacial acetic acid and concentrated
using a Centrivap concentrator attached to a Centrivap cold trap
(Labconco, Kansas City, MO). The dried samples were dissolved in 0.1
M Tris-base, pH 6.8, 1% SDS (final concentration), 1% ␤-mercaptoethanol (final concentration), heated for exactly 75 s at 90 °C, mixed again,
and subjected to SDS-PAGE using 9.5% gels according to the method of
Laemmli (46). Usually, 6 g of total protein per lane were applied.
Protein bands were visualized following staining by Coomassie Brilliant Blue R-250 and destained by diffusion in a methanol/acetic acid/
water solution. In several experiments, proteins were transferred to
polyvinylidene difluoride membranes according to the method described by Towbin et al. (47). Following staining with Coomassie Brillant Blue R and destaining in a solution of acetic acid/methanol/water,
the NH2-terminal sequences of all intermediates were determined using automatic Edman degradation on two separate Applied Biosystems
protein sequencing systems (Procise 494 HT and Procise 494 cLC) in the
laboratory of Dr. Alex Kurosky and Steve Smith (University of Texas,
Medical Branch at Galveston).
Scanning Densitometry of SDS Gels and Calculation of the Rate of
Prothrombin Consumption—The stained gels were scanned with a
Lexmark printer/scanner, and the final images were captured in
PowerPoint. They were subsequently imported as 8-bit grayscale

images into Corel Photo Paint. They were analyzed in the National
Institutes of Health Image module. Bands were isolated, and the total
number of pixels and the average pixel intensities were determined
on a scale from 0 to 255. A region of each lane was chosen as
background. The average pixel intensity of the background was subtracted from that of each band. The total intensity in each band was
then calculated by multiplying the result by the total number of
pixels. To compensate for minor loading differences from lane to lane,
all intensities were normalized to the sum of intensities of all the
bands in each lane. The Coomassie Blue staining intensities of fragment 1䡠2-A and the B chain, relative to prothrombin, were determined
based on the stoichiometric relationship that the sum of prothrombin
plus the B chain is constant throughout the reaction in the presence
of DAPA. Thus, for a given experiment, the intensity data were
subjected to linear regression to the equation, intensity of B chain ⫽
total intensity ⫹ R䡠intensity of prothrombin, where R is the intensity
per mole of B chain relative to that per mole prothrombin. The
relationship was strictly linear for all extents of reaction, as expected.
The value of R was typically ⬃0.65, indicating that, mole per mole,
the B chain stained with 65% the intensity of prothrombin. Thus,
fragment 1䡠2-A, which comprises the part of prothrombin not represented by the B chain, was assigned a relative staining intensity of
0.35. The molar concentration of prothrombin as observed on the gels
was then calculated by normalizing its staining intensity to the initial
prothrombin concentration (usually 1.4 M). The concentrations of
fragments 1䡠2, and the B chain were calculated similarly, except that
their staining intensities were divided by 0.35 and 0.65, respectively.
The linearity of the relationship between amount of protein loaded
and the intensity measured by densitometry was confirmed by loading known quantities of prothrombin and subjecting the stained gels
to the above procedure.
RESULTS

Effect of the Interaction of Factor Va with Factor Xa on the
Rates of Prothrombin-activating Cleavages—To test the effect
of the interaction of factor Va with factor Xa on the rates of
cleavage of prothrombin by prothrombinase, we have used
recombinant factor Va molecules mutated at the factor Xabinding sites and plasma-derived prothrombin. Membranebound factor Xa alone was a poor activator of prothrombin
(Fig. 2A and Table I). In the presence of plasma-derived
factor Va, fragment 1䡠2-A, which is a transient fragment
during prothrombin activation, and results from initial cleavage of prothrombin at Arg320 (Fig. 1), is rapidly consumed
following cleavage at Arg271 to produce fragment 1䡠2 and
thrombin (Fig. 2B, lanes 3–15). Similar results were found in
the presence of wild type factor Va. These combined data
demonstrate that prothrombin activation is significantly accelerated in the presence of the wild type and/or plasma
cofactor molecule (Fig. 2, B and C, and Table I). Analysis of
the products of prothrombin activation by gel electrophoresis
demonstrated that the deficiency in cofactor activity of all
mutant factor Va molecules appears to be a consequence of
delayed thrombin formation because of delayed cleavage at
both Arg320/Arg271 (Fig. 2, D–F). Further, while the rates in
prothrombin consumption were decreased by 3.1- and 2.3-fold
when using factor VaFF and factor VaMI, respectively (Table
I), the rate of thrombin generation was diminished by ⬃17fold with factor VaFF/MI as compared with the rates of thrombin formation in the presence of the wild type cofactor molecule (Table I). The data demonstrate that mutating all four
amino acids in the factor Xa binding site of factor Va heavy
chain has a dramatic effect on factor Va cofactor activity than
disabling either of the two sites individually.
Kinetic Analyses of the Effect of the Mutations in Factor Va on
Prothrombinase Complex Assembly and Function—The efficiency of prothrombinase in activating prothrombin is remarkable when compared with the efficiency of the catalytic subunit
alone, factor Xa, on the same reaction (Refs. 10 and 11; also
illustrated in Fig. 2, A–C). To evaluate the effect of the mutations in factor Va on prothrombinase assembly and function,
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FIG. 3. Determination of the affinity of recombinant factor Va
molecules for plasma-derived factor Xa. Initial rates of thrombin
generation were determined as described under “Experimental Procedures.” Prothrombinase assembled with wild-type factor Va is shown by
filled squares, prothrombinase assembled with factor VaFF is depicted
by filled inverse triangles, prothrombinase assembled with factor VaMI
is depicted by filled triangles, and prothrombinase assembled with
factor VaFF/MI is depicted by filled diamonds. Titrations were carried
out to 20 nM factor Va; however, for graphical purposes the data show
the titration for up to 10 nM cofactor. The solid lines represent a
nonlinear regression fit of the data as detailed under “Experimental
Procedures” using the software Prizm and the model for one binding
site. The apparent dissociation constant (Kapp
D ) for each species was
derived from each titration performed at least in triplicate with four
different preparations of recombinant molecules and is listed in
Table II.

kinetics experiments were designed to determine the dissociation constant for prothrombinase assembly as well as the Km
and kcat values for prothrombinase function. The apparent
dissociation constants (Kapp
D ) for complex formation between
membrane-bound factor Xa and the mutant factor Va molecules was inferred from kinetic experiments in which the
steady-state rate of thrombin generation in the presence of a
fixed concentration of factor Xa, prothrombin, and PCPS was
determined as a function of factor Va (Fig. 3). The Kapp
values
D
derived from these experiments are summarized in Table II.
Wild type factor Va had a similar Kapp
D to plasma-derived factor
Va. The data show that, although factor VaFF and factor VaMI
have ⬃4- and 10-fold lower affinities for factor Xa than wild
type factor Va, factor VaFF/MI has ⬃61-fold lower affinity than
the wild-type cofactor molecule for the enzyme (Kapp
⬃ 10.9
D
nM). These data are consistent with our previous findings using
synthetic peptides (30, 31).
To elucidate which parameters of prothrombinase are affected by mutations in the regulatory subunit, we determined
the kinetic parameters of the enzyme under conditions where
all membrane-bound factor Xa was saturated with factor Va.
Fig. 4 depicts the initial steady-state rate of prothrombin activation as a function of substrate concentration, and the calculated kinetic constants are provided in Table II. The data show
that prothrombinase assembled with recombinant wild type
factor Va as well as with recombinant factor VaFF, recombinant
factor VaMI, and recombinant factor VaFF/MI were characterized by similar Km values (⬃0.15 M). Furthermore, although
prothrombinase assembled with the wild type cofactor molecule had similar kcat as prothrombinase assembled with plasma
factor Va (Table II), prothrombinase assembled with factor
VaFF/MI (30 nM) was characterized by a kcat value of ⬃406 nM
IIa formed䡠min⫺1䡠nM prothrombinase⫺1 (Table II). Similar re-
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sults were found when using factor VaFF/MI at 50 nM (not
shown). Prothrombinase assembled with the other two mutant
recombinant factor Va molecules (5 nM) were characterized by
normal kcat values (1806 and 2040 nM IIa formed䡠min⫺1䡠nM
prothrombinase⫺1, Table II). Comparable results were found
with these two mutant molecules even when used at 30 nM (not
shown). Altogether, these data demonstrate that substitution
of either of the two sets of amino acid residues at the extremities of the factor Xa-binding site of factor Va has no significant
effect for the overall catalysis at saturating cofactor concentrations and appear to be well tolerated by prothrombinase; however, substitution of both sets, all four amino acids, at the same
time has a profound effect on the catalytic efficiency of the
enzyme, decreasing the second order rate constant by ⬃5-fold
(Table II). The inability of factor Xa to function optimally
because of improper interaction with factor Va can be solely
explained by the inability of factor Xa to efficiently convert
prothrombin to thrombin because of diminished productive
collisions (difference in kcat). To quantify the interaction between the mutations in the factor Xa-binding site of factor Va
heavy chain and their synergistic or additive effect on prothrombinase function, we have calculated the difference in free
energy of the transition-state complex of the enzyme assembled
with various mutant cofactor molecules. We have also constructed a thermodynamic cycle for cleavage of prothrombin by
prothrombinase (provided in Scheme I). The positive value of
⌬⌬Gint reveals that mutations at the extremities of the factor
Xa-binding site on factor Va heavy chain are not additive, but
their effect is synergistic and disruptive in nature, resulting in
the destabilization of the transition-state complex and slower
rate of catalysis (41– 45). These data establish the fact that the
interaction of factor Va with factor Xa through amino acids
Glu323, Tyr324, Glu330, and Val331 is crucial for efficient rates of
cleavage of prothrombin by factor Xa.
Cleavage of Mutant Prothrombin Molecules—The kinetic
data obtained with plasma-derived prothrombin were confirmed by using mutant recombinant prothrombin molecules
(Fig. 5). Factor Xa alone was a poor catalyst for cleavage of both
rMZ-II and rP2-II (Fig. 5A). In the presence of plasma and/or
wild type factor Va the expected fragments were obtained following cleavage of rMZ-II (Fig. 5, B and C, lanes 1–9) or rP2-II
(Fig. 5, B and C, lanes 10 –18) (13). Under similar experimental
conditions when using prothrombinase assembled with wildtype factor Va, cleavage at Arg320 in rMZ-II occurred 9-fold
faster than cleavage at Arg271 in rP2-II (Table III). Thus, incorporation of factor Va into prothrombinase is more favorable
for cleavage of prothrombin at Arg320 than for cleavage at
Arg271 (12, 13). Cleavage of rMZ-II and rP2-II in the presence
of prothrombinase assembled with factor VaFF, factor VaMI,
and factor VaFF/MI was considerably delayed compared with
the same cleavages in the presence of the wild type molecule
(Fig. 5, panels D–F, lanes 1–18, and Table III). Interestingly,
factor VaFF and factor VaMI had similar deficiency in cofactor
activity for cleavage of both rMZ-II and rP2-II when compared
with the cleavage of both recombinant prothrombin molecules
by prothrombinase assembled with wild-type factor Va. From
the data shown in Fig. 5F it is also evident that factor VaFF/MI
has the largest deficiency in cofactor activity among the three
molecules, and this is mostly apparent when using rMZ-II
(Table III). These data are confirmatory of our kinetic studies
and the findings with plasma-derived prothrombin.
It is well established that increased catalytic efficiency of
prothrombinase as compared with the catalytic efficiency of
factor Xa alone, is due to the fact that prothrombinase preferentially cleaves prothrombin through pathway II (Fig. 1) (12,
13). Hence, factor Va converts factor Xa from an enzyme that
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TABLE II
Kinetic constants for prothrombinase assembly and function in the presence of various factor Va species

Factor Va species
Plasma factor Va
Wild type recombinant factor Va
Factor VaFF
Factor VaMI
Factor VaFF/MI

K app
D

app
V max

Km

kcat

n Ma
0.29 ⫾ 0.06
0.18 ⫾ 0.02
0.7 ⫾ 0.3
1.8 ⫾ 0.7
10.9 ⫾ 2.4

nM IIa/minb
9.72 ⫾ 0.6
9.85 ⫾ 0.4
9.03 ⫾ 0.2
10.2 ⫾ 0.24
2.03 ⫾ 0.07

Mb
0.12 ⫾ 0.03
0.16 ⫾ 0.02
0.10 ⫾ 0.01
0.14 ⫾ 0.01
0.15 ⫾ 0.02

min⫺1b
1944 ⫾ 120
1970 ⫾ 80
1806 ⫾ 40
2040 ⫾ 48
406 ⫾ 14

kcat/Km

s⫺1䡠M⫺1
2.7 ⫻ 108
2.1 ⫻ 108
3.0 ⫻ 108
2.4 ⫻ 108
4.5 ⫻ 107

Decrease

-foldc

⬵0
⬵0
⬵5

a
Apparent dissociation constants of recombinant factor Va for plasma-derived factor Xa (K app
D ) were determined as described in the legend to
Fig. 3 at limiting factor Xa concentrations (15 pM).
b
Apparent Vmax, Km, and kcat were determined as described in the legend to Fig. 4 at limiting factor Xa concentrations (5 pM) and saturating
concentrations of factor Va.
c
The -fold decrease is the ratio of the second order rate constant (kcat/Km) of prothrombinase assembled with wild type recombinant factor Va
compared to the second order rate constant of prothrombinase assembled with the recombinant mutant factor Va molecules.

FIG. 4. Determination of kinetic parameters of prothrombinase assembled with various recombinant factor Va species.
Initial rates of thrombin generation were determined as described under “Experimental Procedures.” Prothrombinase assembled with two
different preparations of wild type factor Va is shown by filled squares
(5 nM) and filled circles (15 nM), whereas prothrombinase assembled
with plasma-derived factor Va (5 nM) is depicted by filled triangles. The
open diamonds represent prothrombinase assembled with factor VaFF
(5 nM), whereas the open circles show prothrombinase with factor VaMI
(5 nM). Prothrombinase assembled with factor VaFF/MI is depicted by
filled inversed triangles (30 nM). The values of the Km and Vmax extracted from these graphs are listed in Table II.

SCHEME I. Thermodynamic cycle for prothrombin activation
by prothrombinase following substitutions in factor Va that
affect factor Xa binding. ⌬⌬Gint is the free energy of interaction
between the side chains of 323EY324 and 330EV331 of factor Va heavy
chain and was calculated using Equations 2 and 3 described under
“Experimental Procedures.”

slowly cleaves prothrombin initially at Arg271 to an enzyme
that efficiently cleaves prothrombin initially at Arg320. To ascertain the exact activation pathway of prothrombin by prothrombinase assembled with factor VaFF/MI, we followed pro-

thrombin activation by gel electrophoresis under conditions
where factor Xa was saturated with factor VaFF/MI (1 nM factor
Xa with 100 nM factor VaFF/MI, corresponding to ⬃90% saturation of factor Xa). The data demonstrated that prothrombinase
assembled with saturating amounts of mutant cofactor molecule activates prothrombin through pathway II with a slower
rate than that observed for prothrombinase assembled with the
wild type cofactor molecule (data not shown). Cleavage at
Arg320 and meizothrombin formation were considerably delayed. Further, meizothrombin did not accumulate, because the
intermediate was cleaved immediately as it was formed to
produce thrombin. These data verify our findings shown in Fig.
2F and strongly suggest that binding of factor Va heavy chain
to factor Xa is required for efficient initial cleavage at Arg320
and rapid meizothrombin formation. Overall, our findings suggest that the interaction of amino acids Glu323, Tyr324, Glu330,
and Val331 from the heavy chain of factor Va with factor Xa is
required for the positioning of the active site of the enzyme in
a position necessary for optimal productive collisions between
the enzyme and prothrombin, efficient initial cleavage at
Arg320, and competent thrombin formation.
DISCUSSION

Our data demonstrate that binding of the heavy chain of
factor Va to factor Xa through amino acids Glu323, Tyr324,
Glu330, and Val331 is necessary for achieving optimal catalytic
rates for cleavage of prothrombin by prothrombinase. Data
obtained from the crystal structure of meizothrombin desF1
and prethrombin-2 demonstrate that 1) the two prothrombinactivating cleavages are 36 Å apart and 2) for the molecule to
be initially cleaved at Arg320 a rotation of ⬃150° around the
Gly319 and Gly324 hinge points must occur (48 –51). As a consequence, and keeping in mind the results presented herein, it
is logical to hypothesize that the cofactor, factor Va, rather that
being an inert accessory protein, following its incorporation
into prothrombinase and its interactions with factor Xa, directs
catalysis of the substrate by the enzyme at two spatially distinct sites (i.e. Arg320 and Arg271).
Our data show that a mutation at either one of the two
extremities of the factor Xa-binding site on factor Va heavy
chain has no major effect on the kinetic parameters of prothrombinase assembled with saturating concentrations of factor Va; however, substitution of all four amino acids at both
sites simultaneously results in a damaging effect on the ability
of prothrombinase to efficiently convert prothrombin to thrombin through the meizothrombin pathway. These data imply
that amino acid residues 330 and 331 together with any remaining factor Xa-binding site from the heavy chain and/or the
factor Xa-binding site located on the light chain of the cofactor
can compensate for substitutions at amino residues 323 and
324 and vice versa when factor Va is used in excess. However,
substitution of all four amino acid residues at the same time
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FIG. 5. Analysis of the activation of mutant prothrombin molecules by prothrombinase assembled with mutant factor Va
molecules. Mutant prothrombin molecules were incubated in different mixtures with PCPS vesicles, DAPA, and various factor Va molecules (10
nM). The reaction was started by the addition of factor Xa, and the samples were treated as detailed inder “Experimental Procedures.” Lanes 1–9
represent samples of the reaction mixture following incubation of prothrombinase with rMZ-II, before (lane 1), or following 0.5 min, 1 min, 2.5 min,
4 min, 6 min, 10 min, 20 min, and 30 min incubation with factor Xa, respectively; lanes 10 –18 represent samples of the reaction mixture following
incubation of prothrombinase with rP2-II before (lane 10), or following 0.5 min, 1 min, 2.5 min, 4 min, 6 min, 10 min, 20 min, and 30 min incubation
with factor Xa, respectively. A, factor Xa alone no factor Va; B, prothrombinase assembled with plasma-derived factor Va; C, prothrombinase
assembled with wild type factor Va; D, prothrombinase assembled with factor VaFF; E, prothrombinase assembled with factor VaMI; F,
prothrombinase assembled with factor VaFF/MI. Positions of prothrombin-derived fragments are indicated at right as detailed in the legend to figure
2. For the easy reading of the manuscript, the factor Va species used for the reconstitution of prothrombinase are also shown under each panel.
Gels were submitted to scanning densitometry as described under “Experimental Procedures,” and the rates of prothrombin consumption are
reported in Table III.
TABLE III
Rate of activation of recombinant prothrombin derivatives in the presence of various recombinant factor Va species
rMZ-II (cleavage at Arg320)

Enzyme

⫺1

moles consumed䡠s

Factor Xa alone
Prothrombinase
Prothrombinase
Prothrombinase
Prothrombinase

with
with
with
with

wild type
factor VaFF
factor VaMI
factor VaFF/MI

⫺1

䡠mole factor Xa

0.07 ⫾ 0.11
24.6 ⫾ 2.8
2.8 ⫾ 0.2
4.6 ⫾ 0.5
1.4 ⫾ 0.1

Decreasea

rP2-II (cleavage at Arg271)

-fold

⫺1

8.8
5.3
17.6

moles consumed䡠s

Decreasea
⫺1

䡠mole factor Xa

0.05 ⫾ 0.08
2.72 ⫾ 0.23
0.33 ⫾ 0.04
0.52 ⫾ 0.04
0.31 ⫾ 0.06

-fold

8.2
5.2
8.8

a
The -fold decrease is the ratio of the activation rates of recombinant mutant prothrombin molecules in the presence of wild-type factor Va and
mutant factor Va species as measured by the disappearance of prothrombin following scanning densitometry of the gels shown in Fig.5. The final
rate of prothrombin consumption in the presence of prothrombinase assembled with various factor Va species was extracted following plotting of
the data according to the method described under “Experimental Procedures.”

cannot be rescued by any other residue nor by the factor Xabinding site located on the light chain of factor Va resulting in
diminished catalytic rate. Using prothrombinase assembled
with factor VaFF/MI and plasma-derived prothrombin, we have
shown a 16.7-fold decreased rate of prothrombin consumption
compared with the rate of prothrombin consumption obtained
by prothrombinase assembled with the wild type cofactor molecule. A similar decreased rate of prothrombin consumption by
prothrombinase assembled with the same mutant cofactor mol-

ecule under similar experimental conditions (⬃17-fold) was
observed with rMZ-II (which is only cleaved at Arg320). Collectively, the data suggest that prothrombinase assembled with
factor VaFF/MI has a lower kcat because of impaired initial
cleavage at Arg320. These data were confirmed by experiments
studying prothrombin cleavage by prothrombinase saturated
with factor VaFF/MI showing that activation still proceeds
through the intermediate meizothrombin, albeit less efficiently
because of a considerable decrease in the rate of cleavage at
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Arg320. Because factor VaFF/MI is only impaired in its interaction with factor Xa, our findings demonstrate that one of the
roles of factor Va in prothrombinase is to adjust (increase) the
kcat of the enzyme by relocating the amino acids in and/or
around the active site of factor Xa in an optimum position
necessary to efficiently cleave at two sites distant by 36 Å (51).
The thermodynamic data obtained demonstrate that mutation
at residues Glu323, Tyr324, Glu330, and Val331 of factor Va heavy
chain have a cumulative effect on prothrombin catalysis by
factor Xa and suggest that the side chains of these four amino
acids act synergistically to stabilize allosterically the transition
state complex of the enzymatic reaction (41– 45). However, the
change in free energy observed following substitution at the
extremities of the factor Xa-binding site on factor Va could also
be explained by subtle changes in the overall conformation of
the 323–331 amino acid segment due to the two sets of double
mutations. Taken as a whole, the results suggest that the
interaction of factor Va heavy chain with factor Xa is required
for the correct positioning of amino acids in/or around the
active site of factor Xa with respect to the two scissile bonds in
prothrombin, resulting in increased frequency of productive
collisions between enzyme and substrate required for optimum
rates of thrombin formation.
Conclusive evidence for subtle alterations of amino acid residues in and/or around the active site of factor Xa occurring
upon its interaction with factor Va, was provided by studies
using recombinant tick anticoagulant protein (TAP) and a recombinant mutant TAP molecule (Arg3 3 Ala, R3A-TAP) (52–
55). TAP, purified from the soft tick Ornithodoros moubata, is
a potent inhibitor of factor Xa (KI 180 pM), and its potency is
considerably increased toward prothrombinase (KI 5.3 pM) (55).
It has been established that the four NH2-terminal amino acid
residues of TAP are responsible for its inhibitory activity and
interact directly with amino acids from the active site of factor
Xa (56). Further, although R3A-TAP has a 4,000-fold decreased
KI toward factor Xa alone, its potency toward prothrombinase
is only decreased by 30-fold. The fact that factor Va does not
interact with TAP together with results demonstrating decreased inhibitory efficiency of recombinant TAP molecules
mutated at residues Asp47 and Asp54, which were thought to
interact with a site remote from the active site of the enzyme
(3-fold decrease in the KI) (56), led to the suggestion that
prothrombinase exposes cryptic exosites on factor Xa for substrate binding/recognition following incorporation of factor Va
into the complex (54, 55). Because these macromolecular recognition sites on factor Xa that are typically providing a prothrombin binding site in prothrombinase were assumed to be
occupied by R3A-TAP, it was concluded that inhibition of factor
Xa by R3A-TAP is favored kinetically when the enzyme is part
of the prothrombinase complex (53–56). These data are intriguing and of extreme physiological importance, because theoretically R3A-TAP would be able to discriminate between factor
Xa and prothrombinase and could be used as a preventive
therapeutic anticoagulant, albeit its slow on rate (53–55). Notwithstanding the potency of R3A-TAP and its potential therapeutic importance, the crystal structure of recombinant TAPfactor Xa clearly demonstrated that amino acid residues Asp47
and Asp54 from recombinant TAP, which are part of an amino
acid sequence sharing a great deal of homology with prothrombin sequence 305–320 (preceding cleavage at Arg320), interact
with amino acids Lys147, Arg222, and Lys224 from factor Xa,
which in turn are adjacent to the active site of the enzyme (57).
These latter amino acids play a preeminent role in optimum
docking of the inhibitor and appear to be rearranged following
the interaction of factor Xa with factor Va. These data support
the hypothesis that one of the exosites provided by factor Xa

upon its interaction with factor Va for prothrombin tethering
appears to be composed of amino acids near and/or around the
active site of the enzyme promoting optimal docking of the
scissile bonds of the substrate in the catalytic groove of
the enzyme. In conclusion, our findings, put in the context of
the available literature, indicate that factor Va directs catalysis of prothrombin by factor Xa within prothrombinase at two
spatially distinct sites.
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